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The myogenic program is controlled by different groups of transcription factors acting during muscle development, including bHLH muscle
regulatory factors (MRFs), the paired factors Pax3 and Pax7 and the homeobox factors Six1 and Six4. This program is critically dependent on
MRFs that target downstream muscle-specific genes. We now report the expression of Pitx2 and Pitx3 transcription factors throughout muscle
development. Pitx2 is first expressed in muscle progenitor cells of the dermomyotome and myotome. The onset of myoblast differentiation is
concomitant with expression of Pitx3; its expression is maintained in all skeletal muscles while Pitx2 expression decreases thereafter. We have
generated Pitx3 mutant mice and this deficiency does not significantly perturb muscle development but it is completely compensated by the
maintenance of Pitx2 expression in all skeletal muscles. These experiments suggest that Pitx genes are important for myogenesis and that Pitx2
and Pitx3 may have partly redundant roles.
© 2007 Elsevier Inc. All rights reserved.Keywords: Myogenesis; Transcription factors; Knockout mice; DifferentiationIntroduction
The skeletal muscles of the body and limbs are derived from
somites that segment the elongating embryo along the anterior–
posterior axis. The somites rapidly separate into a ventral
mesenchymal compartment, the sclerotome, and a dorso-lateral
epithelial compartment, the dermomyotome. Cells delaminate at
the dorsal and ventral lips of the dermomyotome to form the
myotome along its medial surface (Christ and Ordahl, 1995;
Tajbakhsh and Buckingham, 2000). Multipotent muscle
progenitor cells arising in the dermomyotome acquire definitive
identity through the action of the myogenic regulatory factors☆ Pitx2 and Pitx3 in skeletal muscles.
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doi:10.1016/j.ydbio.2007.04.034(MRFs) Myf5, Mrf4 and MyoD (Rudnicki, 2003; Tajbakhsh et
al., 1996; Kassar-Duchossoy et al., 2004). These progenitors
give rise to muscle precursors, the myoblasts present in the
myotome (Smith et al., 1994; Tajbakhsh, 2003) under the
influence of myogenin, MyoD and Mrf4 (Tajbakhsh and
Buckingham, 2000). The myotome is a transient structure and
its role appears to be the establishment of the original muscle
masses that form through elongation. Myoblasts from the
medial/dorsal myotome will develop into epaxial muscles and
intrinsic back muscles whereas cells of lateral/ventral portion of
the dermomyotome and of the lateral myotome will develop
into hypaxial muscles which include intercostal, abdominal and
limb muscles as well as the diaphragm and tongue muscles
(Buckingham et al., 2003). At the level of developing limbs,
cells that delaminate from the ventral hypaxial lip of the
dermomyotome migrate towards the developing limb buds and
establish themselves in the early muscle territories of the limbs
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2002); these territories appear to be defined independently of
muscle progenitor cells (Kardon et al., 2003). These migratory
cells require Pax3 for proper migration and establishment of
limb muscle masses (Bober et al., 1994; Daston et al., 1996;
Tremblay et al., 1998b). Indeed, a migration defect was ascribed
to the failure to express the receptor tyrosine kinase c-met in the
absence of Pax3 (Bladt et al., 1995; Epstein et al., 1996;
Birchmeier and Brohmann, 2000). Migrating progenitor cells
also express Mox2 and Lbx-1 which are required for migration
and under the control of Pax3 (Mankoo et al., 1999; Mennerich
et al., 1998; Schafer and Braun, 1999; Gross et al., 2000).
Pax7, a Pax3 paralogue, has also been implicated in the
specification of cells that enter the myogenic program. In the
absence of both Pax3 and Pax7, there is a major deficit in
skeletal muscle development with the arrest of the myogenic
program occurring during late embryonic and fetal develop-
ment (Relaix et al., 2005). Indeed in this mutant, cells which
should have expressed these two genes die or change cell
fate. Interestingly, Pax7 is not expressed in early embryonic
muscle progenitors present at the edges of the dermomyo-
tome. Rather, Pax3/Pax7-positive cells are derived from the
central part of the dermomyotome (Ben Yair and Kalcheim,
2005; Gros et al., 2005). These cells can either activate the
myogenic program through the action of Myf5 and MyoD
or remain as a proliferating progenitor population that
reside within the muscle mass (Gros et al., 2005; Kassar-
Duchossoy et al., 2005; Relaix et al., 2005). In late-stage
fetal muscle, these cells adopt a satellite cell position,
suggesting that they can become the pool of adult satellite cells
responsible for postnatal skeletal muscle growth and integrity
(Gros et al., 2005; Kassar-Duchossoy et al., 2005; Relaix et al.,
2005).
Two homeobox genes related to drosophila sine oculis (Six1
and Six4) are also expressed in muscle cells starting in
dermomyotome and myotome (Ozaki et al., 2001; Laclef et
al., 2003; Grifone et al., 2005). Inactivation of both genes
appears to prevent myogenic precursor delamination and
migration, in part through deficient Pax3 expression and in
part through deficient MRF expression (Grifone et al., 2005).
These different studies clearly illustrate that the pathway for
control of myogenesis is not linear and includes many inputs
whose interrelations are not well defined.
Prior work has shown expression of the homeobox
transcription factor Pitx2 in what appeared to be myotomes
and putative migrating myoblasts (Logan et al., 1998; Kioussi et
al., 2002). The related Pitx3 is also expressed in somites (Zhao
et al., 2004) and we have recently identified a muscle-specific
promoter responsible for its expression in myotome and
muscles (Coulon et al., submitted for publication). Otherwise,
Pitx2 has been implicated in left–right asymmetry (Yoshioka
et al., 1998; Logan et al., 1998; Piedra et al., 1998; Ryan et al.,
1998), in cranio-facial development and in pituitary function as
indicated by the name of these factors (Lin et al., 1999; Lu et al.,
1999; Gage et al., 1999). Pitx3 is required for ocular
development (Semina et al., 1997; Semina et al., 1998) and
for the development (Smidt et al., 2004) and maintenance of asubset of midbrain dopaminergic neurons (Smidt et al., 1997;
van den Munckhof et al., 2003, 2006).
We now report the detailed investigation on the expression of
Pitx2 and Pitx3 during myogenesis. Pitx2 is expressed the
earliest in muscle progenitor cells. This expression is followed
and partly overlapping with the appearance of Pitx3 in
differentiated muscle cells. Pitx3 then appears to be widely
expressed in all skeletal muscles of the body and limbs. The
investigation of Pitx3−/− mice indicates that Pitx3 on its own is
not required for myogenesis. However, Pitx2 is strongly
upregulated in the absence of Pitx3 and appears to fully
compensate during muscle formation. Taken collectively, these
data suggest that Pitx genes are important for myogenesis and
that their activities may be partly redundant.Materials and methods
Construction of Pitx3 gene targeting vector
Pitx3 genomic DNA was cloned from a 129sv genomic library. Genomic
fragments corresponding to the Pitx3 locus were cloned into pBluescript KS+
(for construction of a targeting vector, Fig. 5). Homologous recombination with
this vector will lead to insertion of a fragment containing the neomycin
resistance gene flanked by FRT sites and to insertion of LoxP sites upstream of
the neo cassette and downstream of exon 3. Expression of Cre recombinase
should lead to excision of this whole fragment, including Pitx3 exon 3 that codes
for the homeodomain responsible for the DNA binding activity of Pitx3.
ES cell screening and chimeric mouse production
Linearized targeting DNA was electroporated (250 V, 500 μF) into
embryonic stem (ES) cells. ES cells were selected with 250 μg/ml of G418
48 h after electroporation. The DNA of ≈600 resistant clones was analyzed by
Southern blot after digestion. A 3′ genomic fragment was used as external probe.
Three independent homologous recombinant clones were identified and
microinjected into C57BL6 blastocysts for implantation into pseudopregnant
mice. Chimeric males were obtained for the 3 clones and tested for germline
transmission. Two chimeric males were chosen and heterozygous progenies
were generated by backcrosses to C57BL6 and 129/SvJ females. Pitx2−/− and
CMV-Cre transgenic mice were described previously (Gage et al., 1999).
Mouse genotyping
Genotyping was carried out by PCR using DNA isolated from the
umbilical cord/amniotic membrane of the embryos or adult tail sections.
Separate reactions were carried out for Pitx3 and Cre genotyping. Three
specific primers were used for Pitx3 alleles: one forward primer in intron 2: 5′-
GGGAGCGAGAGTGATAACCT-3′, and two reverse primers located in intron
3: 5′-GGAACAGCTCGGGATCAAAG-3′ and in the neomycin gene 5′-TAC-
CGGTGGATGTGGAATGT-3′. Two primers were used for Cre detection:
forward primer 5′-ATCCGAAAAGAAAACGTTGA-3′ and reverse primer 5′-
ATCCAGGTTACGGATATAGT-3′. For embryo studies, noon of the day on
which a vaginal plug was detected was considered as e0.5. Embryos were staged
more precisely by counting the number of somites posterior to the forelimb bud
and scoring the first one counted as somite 13 (Lewandoski et al., 2000).
Preparation and characterization of affinity-purified anti-Pitx2 and
anti-Pitx3 antibodies
Antibodies were raised in rabbits using 100 μgMBP-Pitx2 or MBP-Pitx3 for
the primary injection and three subsequent boosts. Affinity purification was
performed as previously described (Lanctôt et al., 1999b) except that a GST-
Pitx2 or Pitx3 column was used. Two different antisera were produced against
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amino acids 121–180 of mouse Pitx3.
Histology, immunohistochemistry and immunofluorescence
Histology and section immunohistochemistry was performed as described
(Lanctôt et al., 1999a) using rabbit anti-Pitx2 (1/250), rabbit anti-Pitx3 (1/
250) and a previously described rabbit Pitx1 antibody (Tremblay et al.,
1998a). Other primary antibodies were purchased from Pharmingen (anti-
mouse MyoD 1/100 and myogenin 1/100) or from the Developmental Studies
Hybridoma Bank developed under the auspices of the NICHD and maintained
by the University of Iowa, Department of Biological Sciences, Iowa City, IA
52242 (anti-mouse α-actin, MF20 1/20, Pax3 1/100 and Pax7 1/10).
Biotinylated anti-mouse and anti-rabbit (Vector Labs, 1/150) were used as
secondary antibodies and revealed using streptavidin–HRP (NEL 750, NEN,
1/1000) and DAB for immunohistochemistry. Slides were then counter-
stained with Methyl Green. For immunofluorescence, biotinylated anti-rabbit,
anti-mouse-Alexa 488 or 546, and streptavidin-Alexa 488 or 546 (Vector
Labs, 1/150) were used as secondary or tertiary antibodies. Slides were
mounted using Vecta-Shield (Vector Labs). For Pitx3 and Pax7 co-staining,
rabbit anti-Pitx3 (1/250) and anti-rabbit alkaline phosphatase (Vector Labs, 1/
300) were used together with mouse anti-Pax7 (1/10), biotinylated anti-mouse
(Vector Labs, 1/150) and streptavidin–HRP (NEL 750, NEN, 1/1000). The
reactions were revealed using NBT/BCIP (Roche Diagnostics) and NovaRED
(Vector Labs) substrates. No counter-staining was performed and slides were
mounted using aqueous medium (9:1 glycerol/PBS).Fig. 1. Early expression of Pitx2 and Pitx3 genes in muscle cells. Whole-mount in sit
(A–D) and Pitx3 (E–H). At e9.5 (A, E), only Pitx2 is expressed in oral ectoderm and l
myotomes by e11 at the same time as Pitx3 expression in eye lens (F) and Pitx2 in ocu
views), both genes are expressed in all developing muscles (myotome and limbs musc
of e10.5 embryos reveal early Pitx2 and Pitx3 expression in myotome at the forelimb
are both detected in the ventral hypaxial part of the myotome (m) delineated by myo
ventro-lateral lip (vll) of dermomyotome (dm) that stains for Pax3 (K).Whole-mount in situ hybridization
Sections and whole-mount in situ hybridization was performed as described
in the protocols from Dr. Janet Rossant's laboratory using Pitx2 and Pitx3
probes. These two protocols used can be found at http://www.sickkids.ca/
rossant/custom/protocols.asp.Results
Expression of Pitx2 and Pitx3 in muscle cells
The embryonic pattern of Pitx gene expression was revealed
by whole-mount in situ hybridization. For both Pitx2 and Pitx3,
expression was detected in myotome and in forming muscles
masses of limb buds (Figs. 1A–H). This expression appears
later than the Pitx2 expression in oral ectoderm and lateral plate
mesoderm that are already evident at e9.5 (Fig. 1A). Examina-
tion of multiple embryos suggested that myotome expression of
Pitx2 and Pitx3 starts around e10.5 and that both are well
established by e11, with Pitx2 signal appearing stronger than
that of Pitx3 (Figs. 1B and F). By e11.5, both genes appear to
have similar patterns in developing muscles (Figs. 1C and G)u hybridization of wild-type embryos reveals the pattern of expression for Pitx2
ateral plate mesoderm (arrowheads). (B, F) Both Pitx2 and Pitx3 are expressed in
lar muscles (B). By e11.5 (C, G) (lateral views) and e12.5 (D, H) (dorso-posterior
les). Immunohistochemistry experiments performed on serial transverse sections
(I–M) but not at hindlimb (N–R) level. At the FL level, Pitx2 (L) and Pitx3 (M)
genin (I) and MF20 (J) staining while Pitx2 (but not Pitx3) is also expressed in
424 A. L’Honoré et al. / Developmental Biology 307 (2007) 421–433and this is illustrated for hindlimb (HL) muscles at e12.5 (Figs.
1D and H).
In order to correlate the expression of Pitx2 and Pitx3 with
myotome and/or dermomyotome development, sequential
transverse sections from e10.5 embryos taken at the level of
forelimb (FL) and HL buds were analyzed by immunohisto-
chemistry for Pitx factors and for markers of myogenesis (Figs.
1I–R). At the FL level, expression of Pitx2 is first detected in
the hypaxial part of the myotome (Fig. 1L), defined by
myogenin (Fig. 1I) and MF20 staining (Fig. 1J). It is also
expressed in the ventro-lateral lip (vll) of the dermomyotome
(Fig. 1L), delineated by Pax3 staining (Fig. 1K). No expression
is detected at this stage at the HL level (Fig. 1Q). Serial sections
stained for Pitx3 reveal expression in the hypaxial part of rostral
myotomes but not in dermomyotome (Fig. 1M), in contrast to
Pitx2. Interestingly, neither Pitx gene is expressed in less
developed myotomes at HL level (Figs. 1Q, R), whereas Pax3
and myogenin are already detected (Figs. 1N, P), suggesting
that Pitx2 and Pitx3 switch on after myogenic commitment in
myotome. In addition, migratory cells (arrowhead) and HL
precursors expressing Pax3 do not express Pitx genes (Fig. 1P).
At later developmental stages (data not shown), caudal
myotomes exhibit Pitx expression patterns similar to those of
e10.5 rostral myotomes.
Sequential expression of Pitx2 and Pitx3
In order to better define expression of Pitx2 and Pitx3 genes
during myotome development, we investigated their expression
by co-localization with various markers in e11.5 myotomes that
are progressively more advanced in development along the
anterior to posterior axis (Fig. 2). In these embryos, the least
developed myotomes at the caudal end show a significant
number of nuclei positive for Pitx2 (Figs. 2D and J), but very
few positive for Pitx3 (Figs. 2P and V). Co-labeling with
myogenin and MF20 indicates that many cells co-express these
differentiation markers with Pitx2 (Figs. 2F, L1 and 3Y). It is
interesting to note that Pitx2-positive and MF20-negative cells
are present at the ventral lip of the dermomyotome (Fig. 2L2).
Taken together, these data suggest that Pitx2 is expressed before
Pitx3 in myotome; in agreement with its expression in vll (Figs.
1L and 2L2), Pitx2 may be associated with cell progression
from dermomyotome to myotome.
The same co-labeling experiments were performed in more
advanced rostral somites and showed a majority of Pitx3-
positive cells co-expressing myogenin (Figs. 2M–O, 3Z) and
MF20 (Figs. 2S–U). In contrast, only a fraction of Pitx2-
positive cells express these markers (Figs. 2A–C, G–I, 3Y).
These results suggest that Pitx3 is expressed in differentiated
myotome cells, and that Pitx2 may be expressed earlier in
muscle progenitors and precursors.
Pitx2 is expressed in muscle precursors while Pitx3 appears at
differentiation
In order to determine if the Pitx2-positive MF20-negative
cells of the myotome and vll are muscle progenitor cells, weperformed co-staining of Pitx2 with Pax3 (Figs. 3A–C):
indeed, many of these vll cells co-express Pitx2 and Pax3
(Fig. 3C2). In the central myotome, most Pitx2-positive cells
are also Pax3-positive (Fig. 3C1). We then checked Pitx2 and
Pitx3 expression at limb level in migrating myoblast
precursors by co-labeling with Pax3; we did not find any
co-labeling in migrating cells in agreement with Figs. 1K, L
and P, Q. Interestingly, all Pax3-positive cells that have
completed migration at the proximal limb bud also express
Pitx2 (Figs. 3D–I). However, all Pitx2-positive cells are not
positive for Pax3: these may represent myoblast cells that
have entered differentiation. In parallel co-labeling experi-
ments, Pitx3 was never co-expressed with Pax3 (data not
shown).
Pax7 is expressed with Pax3 in a large subset of muscle
progenitors (Relaix et al., 2005). In agreement with the
interpretation that muscle progenitors express Pitx2, we found
extensive co-labeling of myotome cells with Pitx2 and Pax 3
(Fig. 3C1), and with Pax7 (Figs. 3J–L). In order to assess
whether Pitx2-positive cells are indeed proliferating progeni-
tors, we performed BrdU incorporation in e11.5 embryos
(Figs. 3M–O, Y). Analysis of developing FL muscle masses
indicated that a large number of Pitx2-positive cells
incorporated BrdU (Figs. 3O, Y). In contrast, co-staining
for Pitx3 revealed fewer double-positive cells with BrdU
(Figs. 3V–X, Z). Phospho-histone H3 is a marker of early
mitosis and in agreement with the idea that Pitx2-positive
progenitors are in proliferation, we detected cells positive for
both Pitx2 and phospho-H3 in interlimb myotomes of e11.5
embryos (Figs. 3P–R, Y). In contrast, double-positive cells
for phospho-H3 and Pitx3 could only rarely (about 1.5%) be
observed (Fig. 3Z), suggesting that the few Pitx3- and BrdU-
positive cells (Figs. 3X, Z) correspond to cells that recently
exited the cell cycle. In order to test the idea that Pitx3
switches on at the onset of muscle differentiation, we did co-
labeling of myotomal and limb muscle masses with Pitx3 and
the MRFs MyoD and myogenin (Fig. 3Z). Whereas in
myotome, about 80% of Pitx3-positive cells are also
myogenin-positive, we observed fewer double-positive cells
in limb muscles (about 40%); it is however noteworthy that
all limb bud myogenin-positive cells are also Pitx3-positive
(Figs. 3S–U). It is also interesting to note different pro-
portions of double MRF- and Pitx2-positive cells in myotome
compared to limb muscle masses (Fig. 3Y). These data may
suggest that Pitx3 expression precedes MRFs in limb bud
muscles, in contrast to myotomes.
Maintenance of Pitx3 and decreasing Pitx2 expression
Whole-mount in situ hybridization revealed that both Pitx2
andPitx3 genes have similar patterns of expression in embryonic
developing muscles (Fig. 1). Since Pitx3 early expression
suggests widespread presence in all skeletal muscles, we verified
its expression in muscles of e15.5 embryos by in situ
hybridization. This analysis (Figs. 4A–C) confirmed Pitx3
mRNA in HLmuscles as well as in abdominal and back muscles
that derive from hypaxial and epaxial myotome, respectively.
Fig. 2. Pitx2 and Pitx3 are expressed sequentially. Double staining experiments for Pitx2 (A, D, G, J) or Pitx3 (M, P, S, V) and myogenin (B, E, N, Q) or MF20
(H, K, T, W) were performed on transverse sections of e11.5 embryos at rostral (A–C, G–I), thoracic (M–O, S–U) and caudal (D–F, J–L, P–R, V–X) levels.
Pitx3 expression in caudal myotome is restricted to a few cells (P–R, V–X), whereas a significant number of cells are positive for Pitx2 (D–F, J–L). A majority
of these cells co-express both myogenin (D–F) and MF20 (J–L, L1), but interestingly, a population of Pitx2-positive cells located in the ventro-lateral part of
dermomyotome (L2) do not express MF20. The same co-staining performed at thoracic and rostral levels show a large number of Pitx3-positive cells that mostly
co-express myogenin (M–O) and MF20 (S–U), whereas only a fraction of Pitx2-expressing cells are positive for these markers (A–C, G–I).
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in developing muscles, we followed their expression during
fetal development in a variety of muscles. While Pitx2
expression is already well established at e11.5 in shoulder
girdle muscle (Fig. 4D) together with MyoD and myogenin
(Figs. 4F, G), fewer Pitx3-positive cells are detected in these
muscles (Fig. 4E). In contrast, by e13.5 the same muscles
exhibit a strong Pitx3 signal (Fig. 4I), but greatly decreased
Pitx2 (Fig. 4H). This switch in relative expression of Pitx2
and Pitx3 is also evident for many muscles on a low
magnification view of e13.5 FL (Figs. 4L, M). It is interesting
to note that staining of serial limb sections for Pitx2, Pitx3and α-actin showed a close correlation between Pitx3, but
less so for Pitx2, and α-actin expression (data not shown), in
agreement with the conclusion that Pitx3 is expressed in
differentiated muscle cells. This is further supported in e17.5
muscles that all show strong Pitx3 expression (Fig. 4Q) but
very weak Pitx2 (Fig. 4P). In order to directly assess Pitx3
expression in satellite cells, we did co-labeling of e18.5
hindlimb muscles with Pitx3 and Pax7 (Fig. 4R). This
analysis revealed that most Pax7-positive nuclei are also
Pitx3-positive, in addition to a population of Pitx3 single-
positive nuclei. These data indicate expression of Pitx3 in
both muscle fiber and satellite cells.
Fig. 3. Pitx2 is expressed in proliferative progenitors while Pitx3 is induced at the onset of differentiation. Co-staining experiments for Pitx2, Pitx3, Pax3, Pax7, BrdU,
phospho-histone H3 or myogenin were performed on transverse sections of e11.5 embryos at caudal myotome (A–C), HL bud (D–I), FL (M–O, S–U), interlimb
(P–R, V–X) and rostral myotome (J–L) level. Pitx2 is co-expressed with Pax3 (A–C) in cells of the myotome (C1), of the ventro-lateral edge of the dermomyotome
(C2) and in limb bud progenitor cells (circled in panels D–F, enlarged in panels G–I), while no Pitx3 and Pax3 co-staining can be detected in consecutive sections
(not shown). Pitx2-positive cells of the myotome are also mostly positive for Pax7 (J–L). A large number of Pitx2-expressing cells incorporated BrdU in FL muscle
masses (M–O) indicating that they were in proliferation whereas only a few Pitx3-positive cells stained for BrdU at thoracic level (V–X). Proliferation of Pitx2-
positive cells was confirmed by phospho-histone H3 (pH3) co-staining (P–R) but co-staining could not be observed with Pitx3 (not shown), suggesting that the few
BrdU-positive Pitx3-positive cells observed in panels V–X were just completing their last cell cycle. A subset of Pitx3-positive cells of FL muscle masses express
myogenin (S–U), suggesting that Pitx3 switches on in early differentiating cells. (Y, Z) Quantitation of cells double-positive with Pitx2 (Y) or with Pitx3 (Z). Data
are means±SEM for triplicate counts of at least 100 cells.
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Fig. 4. Maintenance of Pitx3 and decreasing Pitx2 expression. In situ hybridization performed withMyoD (A) and Pitx3 (B) probes on thoracic transverse sections of
e15.5 embryos reveal that both are co-expressed in all back (b), abdominal (ab) and HL muscles. Bl, bladder; tl, tail. Immunohistochemical localization of Pitx2, Pitx3,
MyoD and myogenin in sagittal FL (D–O) and HL (P, Q) sections of e11.5 (D–G), e13.5 (H–O) and e17.5 (P–Q) embryos. At e11.5, shoulder girdle muscles already
express Pitx2 (D) as well as MyoD (F) and myogenin (G), but not Pitx3 (E). The same muscles examined in e13.5 embryos (H–K) show a switch of relative expression
between Pitx2 and Pitx3: a strong expression of Pitx3 is detected (I), while Pitx2 expression is decreasing (H). Similar distributions were observed in e13.5 FL muscles
(L–O) and e17.5 HL muscles (P, Q). (R) At e18.5, co-immunostaining was performed for Pitx3 (blue staining) and Pax7 (red staining). Pitx3 was detected in myofiber
nuclei (Pax7-negative nuclei marked by asterisk) and in satellite cells (Pax7-positive nuclei marked by arrows).
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Since Pitx3 is the most widely expressed Pitx factor in
fetal muscles (Fig. 4), we undertook to knockout this gene.
For this purpose, the naturally occurring Pitx3 mutant, the
aphakia mouse, is not useful since this mouse retains
muscle expression of Pitx3 (Coulon et al., submitted for
publication). For Pitx3 gene inactivation, we targeted the
third exon of the gene that encodes the homeodomain (Fig.
5A). LoxP sites were introduced upstream and downstream
of exon 3 in a vector that also contains a PGKneo cassette
flanked by FRT sites. These FRT sites will permit in vivo
deletion of the neo cassette if required (Dymecki, 1996).
The Pitx3flox-neo allele was generated through homologous
recombination in isogenic 129 mouse embryonic stem (ES)
cells. Southern blotting using a 3′ probe located outside ofFig. 5. Targeted disruption of the mouse Pitx3 gene. (A) Schematic representation of
gene with its exons in open boxes. Upon successful homologous recombination, the P
the PGKneo gene and the open arrows indicate the position the LoxP sites. Upon dele
analysis (left) of tail DNA digested with XbaI and hybridized with the probe indicated
genomic DNA from embryos used for genotyping as described in Materials and metho
type littermate (top).the targeted sequences (Fig. 5A) identified 7 correctly
targeted clones among ≈600 tested (Fig. 5B). Of three ES
clones that were selected and used for blastocyst injection,
two transmitted the floxed allele to the germline and were
interbred with C57BL6 and 129SV females. Pitx3+/flox mice
obtained in both genetic backgrounds were mated with mice
expressing Cre recombinase under the control of the CMV
promoter. Deletion of the third exon of the Pitx3 gene was
confirmed by PCR analysis (Fig. 5B). Pitx3+/− mice are
viable, fertile and did not present any obvious phenotype.
To analyze the effect of Pitx3 loss-of-function, Pitx3+/−
mice were intercrossed. Pitx3−/− mice in both genetic back-
grounds are viable, fertile, and have a life expectancy
similar to wild-type siblings despite the absence of muscle
Pitx3 protein (Figs. 7I–L). Further investigation of Pitx3−/−
animals showed eye dysmorphogenesis (Fig. 5C) andthe Pitx3 gene with its exons shown in black boxes and of the downstream cig30
itx3flox allele was obtained as shown for the targeted gene in which neo represents
tion by cre recombinase, the Pitx3null (−/−) allele was obtained. (B) Southern blot
in panel A reveal mice harboring the three Pitx3 alleles. PCR analysis (right) of
ds. (C) Eye phenotype of a newborn Pitx3−/−mouse (bottom) compared to wild-
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and not worse than aphakia mice (data not shown), but did
not reveal any gross defect in musculature.
Despite the absence of an apparent muscle phenotype, we
investigated Pitx3−/− embryos for expression of muscle
markers that may reveal partial defects in myogenesis. No
defects could be observed in e11.5 myotome (Figs. 6A–H), in
developing e11.5 intercostal muscles (Figs. 6I–N), or in e13.5
FL muscle masses (Figs. 6O–R) or in e17.5 HL muscles
(Figs. 6S–V). Analysis of these different muscles at different
times in their development indicated no differences in the
patterns of expression for Pax3 (Fig. 6E), MyoD (Figs. 6F, L,
R, V), myogenin (Figs. 6G, M), MF20 (Figs. 6H, N) or Pax7
(Figs. 6Q, U) compared to heterozygous siblings (Figs. 6A–
D, I–K, O–P, S–T).Fig. 6. Embryonic and fetal myogenesis occur normally in Pitx3−/− mice. Immunohi
sections of e11.5 (A–N), e13.5 (O–R) and e17.5 (S–V) embryos did not show any di
not impair early somitic differentiation: e11.5 caudal myotomes show similar immu
(I–V) Absence of Pitx3 does not impair expression of MyoD (I, L), myogenin (J, M
(O, Q, S, U) and MyoD (P, R, T, V) in e13.5 FL muscles (O–R) as well as inCompensation of Pitx3 deficiency by Pitx2
Since Pitx2 is expressed early during myogenic differ-
entiation, we tested whether its expression might be altered in
the absence of Pitx3. All muscles of Pitx3−/− embryos
examined showed no immunoreactivity for Pitx3 (Figs. 7I–L)
whereas their wild-type counterparts showed expression in
almost all nuclei (Figs. 7A–D); this included paravertebral
(A, E, I, M), intercostal (B, F, J, N), lower back (C, G, K, O)
as well as hip muscles (D, H, L, P) of e15.5 embryos. As
shown previously (Fig. 4), these muscles express very low
levels of Pitx2 in wild-type embryos (Figs. 7E–H). In striking
contrast, the same muscles of Pitx3−/− embryos exhibit robust
Pitx2 immunoreactivity (Figs. 7M–P), indicating that Pitx2
expression is compensating for the absence of Pitx3 in thesestochemical analysis of muscle markers on transverse (A–H) and sagittal (I–V)
fference between Pitx3−/− and Pitx3+/− littermates. (A–H) Absence of Pitx3 does
nostaining for Pax3 (A, E), MyoD (B, F), myogenin (C–G) and MF20 (D–H).
) or MF20 (K, N) in e11.5 inter-costal muscle masses, or expression of Pax7
e17.5 HL muscles (S–V).
Fig. 7. Pitx2 compensates the loss of Pitx3 in muscles of Pitx3−/−mice. Expression of Pitx2 (E–H, M–P) and Pitx3 (A–D, I–L) revealed by immunohistochemistry on
sagittal sections of e15.5 Pitx3−/− (I–P) and Pitx3+/+ (A–H) embryos. In wild-type embryos (+/+), Pitx3 is detected in most nuclei of para-vertebral, inter-costal, lower
back and hip muscles (A–D) whereas Pitx2 expression is relatively weak (E–H). In contrast, Pitx2 is strongly expressed in most nuclei of the same muscles of Pitx3−/−
embryos (M–P) that no longer express Pitx3 (I–L).
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ism exists to maintain a level of Pitx transcription factors in
muscle cells and that this mechanism can feedback onto the
Pitx2 gene in absence of Pitx3 resulting in complete
compensation (Fig. 8C).
Discussion
The present work identifies the Pitx transcription factors as
markers of skeletal muscle development (Fig. 8). All skeletal
muscles of the body and of the limbs express Pitx3 and this
expression correlates closely with the expression of muscle
markers and with the onset of myogenic differentiation. Pitx3
expression is preceded by Pitx2 in myotome and in limb muscle
progenitors (Fig. 8A). The knockout of Pitx3 expression does
not impair muscle development in any significant way and it
appears that Pitx2 completely compensates through enhanced
and prolonged expression for the loss of Pitx3 (Figs. 6, 7).
Pitx2 in muscle progenitor cells
The earliest expression of Pitx2 appears to be in
undifferentiated muscle progenitors of the myotome and
ventro-lateral lip of the dermomyotome: these cells co-express
Pax3 (Figs. 3A–C) and Pax7 (Figs. 3J–L) but do not express
MF20 (Fig. 2L). Progenitors of developing limb muscle
masses also co-express Pax3 and Pitx2 (Fig. 3D–F) and alarge number of these are positive for BrdU (Figs. 3M–O, Y)
and for phospho-H3 (Figs. 3P–R, Y) indicating that they are
in proliferation. However, Pitx2 expression is not restricted to
undifferentiated proliferating cells since the myotome and
forming muscles contain a large number of cells that co-stain
for Pitx2 and myogenin (Figs. 2A–F, Y) and for MF20 (Figs.
2G–L). The expression of Pitx2 is strongest in early muscle
cells from about e10.5 to e12.5. Thereafter, Pitx2 expression
decreases in all muscle masses to be apparently replaced by
Pitx3 (Figs. 4 and 8A). In all developed muscles at e17.5,
expression of Pitx2 is very discrete with a few nuclei often
observed in clusters or within the same fiber (Figs. 7E–H).
The nature of those cells/fibers remains undefined. The co-
expression of Pitx2 with Pax3 in proliferating BrdU-positive
cells may be suggestive of a role in proliferation of pro-
genitors (Kioussi et al., 2002; Baek et al., 2003; Martinez-
Fernandez et al., 2006). If so, its replacement by Pitx3 in
differentiated post-mitotic muscle cells may be a way to
maintain a Pitx-dependent myogenic program of gene
expression independently of a Pitx2 proliferative activity
that may not be shared by Pitx3. Should Pitx2 have such role
in muscle progenitor proliferation, it is clear that it is not the
sole regulator of proliferation as its maintenance in Pitx3−/−
muscles did not lead to bigger or dysmorphic muscles (data
not shown).
A recent study of lacZ expression from a Pitx2 gene
insertion showed similar Pitx2 expression patterns as we
Fig. 8. Schematic representation of the expression of Pitx2 and Pitx3 in myogenic lineages. (A) The least differentiated cells that express Pitx2 are in the ventro-lateral
lip (vll) of the dermomyotome (DM) and the progenitor cells that populate the limb muscle territories; these cells do not express Pitx3. The onset of myogenic
differentiation in both myotome (M) and limbs is accompanied by Pitx3 expression that eventually becomes predominant as myoblasts differentiate into myocytes and
myotubes. (B) Expression of cell markers during myogenic differentiation. Pitx2 is expressed in both Pax3 and Pax3+Pax7 progenitors. The myoblast precursors
switch on Pitx3 expression that replaces Pitx2 almost completely in differentiated muscle cells. (C) In Pitx3−/− embryos, Pitx2 expression is not switched down and
compensates for Pitx3 deficiency in all muscles.
431A. L’Honoré et al. / Developmental Biology 307 (2007) 421–433report here (Shih et al., 2007). However, there appears to be
significant discrepancies: for example, Shih et al. report lacZ
expression in migrating myoblast and in late stage and adult
muscles. We did not find significant Pitx2 immunoreactivity
in these tissues compared to e10.5–e12.5 embryos (Figs. 2–4). These differences may be due to the stability of the lacZ
protein and/or to the greater sensitivity of lacZ relative to
immunoreactive Pitx2 detection. The lacZ expression may be
indicative of weak Pitx2 promoter activity but very low
protein accumulation: a similar situation has been proposed
432 A. L’Honoré et al. / Developmental Biology 307 (2007) 421–433for Myf5 (Smith et al., 1994; Cornelison and Wold, 1997;
Cooper et al., 1999; Beauchamp et al., 2000). Similarly, the
adult Pitx3−/− muscles did not show more Pitx2 expression
than wild-type animals (data not shown).
Pitx3 is expressed at the onset of muscle cell differentiation and
is maintained in all skeletal muscles
In contrast to Pitx2, Pitx3 is rarely associated with phospho-
H3-positive cells (Figs. 3Y, Z) and is less present in BrdU-
positive cells (Figs. 3V–Z). In myotome, Pitx3 is detected in
cells that have entered myogenic differentiation as they are, for
the most part, already positive for myogenin (Figs. 2M–R, 3Z),
for MF20 (Figs. 2S–X) and for MyoD (Fig. 3Z). In contrast,
Pitx3 expression in limb bud muscle masses is more widespread
than myogenin (Figs. 3S–U) or MyoD (Fig. 3Z and data not
shown). This may suggest that Pitx3 expression may precede
MRFs in limb muscle cells: the detection of BrdU- and Pitx3-
positive cells (Fig. 3Z) is consistent with this interpretation and
may indicate induction of Pitx3 immediately following pre-
cursor cell cycle exit.
Pitx3 expression is maintained widely in more mature
muscles (Fig. 4). This expression of Pitx3 in differentiated
cells suggests that it may also function in the maintenance of
the muscle phenotype. This idea is entirely consistent with
the observation that Pitx transcription factors contribute to
transcriptional activation of many muscle-specific genes such
myogenin, slow and fast troponin. Indeed, we have shown
that the action of Pitx factors on muscle-specific regulatory
sequences is exerted in synergism with MRFs. Transcrip-
tional synergism between MRF heterodimers and Pitx factors
is readily accounted for by the previous demonstration that
the bHLH domains of ubiquitous bHLH factors that are the
dimerization partners of MRFs, can physically interact with
the Pitx homeodomain for transcriptional synergism: this
paradigm was demonstrated previously for interactions
between Pitx1 and bHLH heterodimers containing the
neurogenic bHLH, NeuroD1 (Poulin et al., 2000). It also
appears that MRFs exert a positive feedback effect on the
Pitx3 gene promoter (Coulon et al., submitted for publica-
tion) and MyoD was shown to be present at the Pitx3
promoter in ChIP experiments (Blais et al., 2005). This
positive feedback interaction between MRFs and Pitx3 taken
together with the synergistic activation of muscle-specific
genes by Pitx factors and MRF heterodimers strongly
suggest that Pitx factors constitute an essential component
of the myogenic differentiation and gene expression program.
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